201 related articles for article (PubMed ID: 12631396)
1. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
[TBL] [Abstract][Full Text] [Related]
2. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
3. c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?
Schmitt FC; Reis-Filho JS
Breast Cancer Res; 2003; 5(4):188-91. PubMed ID: 12817989
[TBL] [Abstract][Full Text] [Related]
4. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
5. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
6. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
7. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
10. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
Ismail MF; Aly MS; Khaled HM; Mohamed HM
Ger Med Sci; 2009 May; 7():Doc03. PubMed ID: 19675743
[TBL] [Abstract][Full Text] [Related]
11. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
12. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
13. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
14. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
Roux-Dosseto M; Romain S; Dussault N; Desideri C; Piana L; Bonnier P; Tubiana N; Martin PM
Eur J Cancer; 1992; 28A(10):1600-4. PubMed ID: 1356387
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
Berns EM; Foekens JA; van Putten WL; van Staveren IL; Portengen H; de Koning WC; Klijn JG
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):13-9. PubMed ID: 1356012
[TBL] [Abstract][Full Text] [Related]
17. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
19. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Horsfall DJ; Firgaira F; McCaul K; Setlur V; Chalmers AH; Yeo R; Ingram D; Dawkins H; Hahnel R
Int J Cancer; 1994 Jan; 56(1):61-5. PubMed ID: 8262679
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
